IFNA1 and COVID-19: Since the COVID-19 pandemic, IFNs have been evaluated in several randomized controlled trials as attractive therapeutic candidates due to their plausible mode of action, suppression of IFN activity in severe COVID-19, and inhibition of SARS-CoV-2 replication in vivo and in vitro [14].